TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06090188

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A Culture-Based Multicomponent Cognitive Training Program
Description: Activities of the program were structured, cognitive, leisure activities based on Chinese and Taiwanese culture for cognitively impaired older people. Activities contained structured brain-exercise activities and musical activities. The structured brain-exercise activities included playing musical instruments or singing, playing board games, and classes in Chinese, sciences, sociology, physical education, cooking, and math. Chinese and Taiwanese cultures were included within the structured brain-exercise activities curriculum, such as food, clothing, architecture, places of interest, folklore, etiquette, celebrations, religion, art, etc. Participants began with a musical exercise, then had 20-30 minutes of physical exercise with 5 minutes of warm-up at the beginning and 5 minutes of cool down. The program was provided for at least 40-60 minutes, twice a week, for 8 weeks via RAs and day centre caregivers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Culture-Based Multicomponent Cognitive Training Program
Description: Activities of the program were structured, cognitive, leisure activities based on Chinese and Taiwanese culture for cognitively impaired older people. Activities contained structured brain-exercise activities and musical activities. The structured brain-exercise activities included playing musical instruments or singing, playing board games, and classes in Chinese, sciences, sociology, physical education, cooking, and math. Chinese and Taiwanese cultures were included within the structured brain-exercise activities curriculum, such as food, clothing, architecture, places of interest, folklore, etiquette, celebrations, religion, art, etc. Participants began with a musical exercise, then had 20-30 minutes of physical exercise with 5 minutes of warm-up at the beginning and 5 minutes of cool down. The program was provided for at least 40-60 minutes, twice a week, for 8 weeks via RAs and day centre caregivers.
Study: NCT05410080

Intervention type: DIAGNOSTIC_TEST
Intervention: Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study
Description: Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study

Intervention type: DIAGNOSTIC_TEST
Intervention: Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study
Description: Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study
Study: NCT05106777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle.
Study: NCT04695405

Intervention type: GENETIC
Intervention: Saliva Genetic Samples
Description: Patients will provide two saliva swabs containing genetic materials.
Study: NCT04821557

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protease + Protein
Description: Participant will consume a microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Protein
Description: Participant will consume a placebo supplement (250 mg maltodextrin) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
Study: NCT06254937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reproductive Life Plan training
Description: Reproductive Life Plan trainings; It will be done in the form of group training, which is considered an advantageous health education method in terms of low cost, wide scope and practicality. During the training, after the power point presentation to the initiative group, question-answer, discussion, brainstorming and visualizations will be made with the Pecha Kucha Technique. Presentations prepared in line with the Reproductive Life Plan Training Booklet will be used as training tools. Training will be given to participants face to face for 40 minutes, once a week for five weeks. Each training session will include two topics in booklet.
Study: NCT04743609

Intervention type: DIAGNOSTIC_TEST
Intervention: nasopharyngeal samples
Description: rapid antigen test for Sars Cov-2, influenza and RSV. multiplex RT-PCR for a subgroup of 500 patients

Intervention type: DIAGNOSTIC_TEST
Intervention: nasopharyngeal samples
Description: rapid antigen test for Sars Cov-2, influenza and RSV. multiplex RT-PCR for a subgroup of 500 patients

Intervention type: DIAGNOSTIC_TEST
Intervention: nasopharyngeal samples
Description: rapid antigen test for Sars Cov-2, influenza and RSV. multiplex RT-PCR for a subgroup of 500 patients
Study: NCT05104489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimrSC-2f
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimrSC-2f
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimrSC-2f
Description: IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AdimrSC-2f
Description: IM injection
Study: NCT05733195

Intervention type: OTHER
Intervention: OGTT test
Description: The OGTT test (75g glucose) was performed between 24 and 28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG.

Intervention type: OTHER
Intervention: OGTT test
Description: The OGTT test (75g glucose) was performed between 24 and 28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG.
Study: NCT05549284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib,Rituximab and Methotrexate
Description: Orelabrutinib, Rituximab combined with high-dose Methotrexate(RMO) as first line regimens in the treatments of newly diagnosed primary central nervous system lymphoma. The response will be evaluated every 2 cycles. Patients who achieved complete remission (CR) or partial remission (PR) will receive further treatment, and there are 6 cycles of RMO regimen for the induction. The patients with stable disease (SD) or progressed disease(PD) will withdraw from the trial and receive salvage regimens. After total 6 induction cycles, the investigators evaluate the efficiency again. After 6 cycles, the patients who receive CR or PR, can tolerate Autologous Hematopoietic Stem Cell Transplantation (AHSCT) will be candidates of high-dose chemotherapy and stem rescue. The patients who achieve CR or PR, cannot tolerate AHSCT will go to whole brain radiotherapy or Orelabrutinib maintenance. The patients with SD or PD will receive salvage regimen.
Study: NCT05145283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conestat alfa (Ruconest®)
Description: In the current study, participants will receive two intravenous injections of conestat alfa (immediately during the TAVI procedure and again 3h later) at a dose of 100 U/kg (first dose) and of 50 U/kg (subsequent dose), for patients less than 84 kg; two intravenous injections (immediately during the TAVI procedure and again 4h later) of conestat at a dose of 8400 U (4 vials, first dose) and of 4200 U (2 vials, subsequent dose) for patients of 84 kg body weight or greater. The chosen regimen including repeated administration should increase and maintain serum C1INH levels above twice the serum concentration for six to eight hours in the majority of patients. The timeframe of therapeutic concentrations will cover the period of the TAVI procedure itself and the immediate postprocedural period during which reperfusion and additional ischemic events related to global hypoperfusion may occur.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%)
Description: Normal saline (NaCl 0.9%) will serve as placebo treatment. The respective amount of saline (according to patient weight matching the volume of conestat alfa that would have been used for this patient) will be withdrawn in an opaque syringe for slow IV injection.
Study: NCT04832113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity and Dietetic
Description: session in addtion conventional management dietetic, hydratation and physical activity
Study: NCT05554497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction curriculum
Description: Standard 8-week mindfulness-based stress reduction curriculum
Study: NCT05568134

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: An oral glucose tolerance test will be completed. A fasting glucose will be measured.~Participants will drink 1.75 g/kg of dextrose (up to a maximum of 75 grams) within 10 minutes. Glucose values will be measured at 1 hour and 2 hours.
Study: NCT04838847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV Vaccine
Description: Intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV Vaccine
Description: Intramuscular (IM) injection
Study: NCT05417412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy
Description: 8-12 sessions of brief behavioral therapy administered by behavioral health / mental health staff at participating community health centers (CHCs)
Study: NCT04651478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation+Motor Imagery through BCI
Description: Patients will undergo the treatment through the NeuRow platform. NeuRow is a gamified Brain-Computer Interface training paradigm in Virtual Reality (or neurogame) that allows patients to perform the same actions as they would do in real-life by imaging the movement. In NeuRow, patients will see a boat and two high fidelity virtual arms gripping two oars in the first-person view. Patients will have to imagine the movement of each corresponding hand to rotate each oar and progress, observing the movement imagined on screen. The goal of the task is to collect as many flags as possible in a fixed amount of time. In order to improve adherence, the number of flags collected will be recorded in each session. It will be able to adapt the boat speed, turn speed, and cut-off angle, to help patients not to deviate in excess from the target. The treatment itself will be performed for 20 minutes each session, divided into 4 series of 5 minutes to prevent fatigue.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Action Observation through non-related with movement illustrations
Description: The same configuration will be applied to simulate a BCI task, but playing a video about graphic illustrations, people's faces, and landscapes, never related to human movement. They will address interesting and changing topics to avoid patient's boredom. The control session will last 20 minutes, also divided into 4 series of 5 minutes and the therapist will give the instructions of observing and relax.
Study: NCT05528172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripasudil
Description: K-321 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripasudil
Description: K-321 ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ophthalmic solution
Study: NCT05495321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interleukin-2
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once every other day, for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once every other day, for 6 months.
Study: NCT05262517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: 75 mg ODT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT06431100

Intervention type: BIOLOGICAL
Intervention: TCR T-cells
Description: The strengthened T cells are re-infused into the patient to achieve the killing effect
Study: NCT06514079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal dilatation with steroids injection
Description: Under general anesthesia with the patient in the left lateral position. A single-channel endoscope was used. Endoscopic bougie dilatation was performed using Wire-guided Polyvinyl dilator Savary Gilliard/SG. Long-acting steroids triamcinolone acetonide was injected via 25-gauge sclerotherapy catheter. One mL solution of triamcinolone acetonide 40mg/ml was diluted with one mL of saline, in a 2 mL disposable syringe, and 0.5 mL each was injected at the proximal margin of the stricture in four quadrants, 2 mL solution in four quadrants
Study: NCT06444334

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level Diode Laser
Description: Group 2 was exposed to laser irradiation following implant insertion for 3 sessions: Immediately after implant insertion, 2 days after implant insertion and 1 week after insertion , using a red Diode(gallium-aluminun-arsenide) LLLT using calibrated diode laser device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRF platelet rich fibrin
Description: The preparation method of PRF was performed in accordance with the protocol developed by Choukroun et al 2001. PRF was withdrawn and processed from the same operated-on patient's blood; 6ml IV blood withdrawn from the antecubital vein in to two sterile 3ml red vacutainer tubes without anticoagulant, followed by a 12 minute centrifuge with 3000 RPM producing a platelet rich fibrin clot, which is then incised \& separated with 2mm basal layer of RBCs rich in growth factors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF platelet rich fibrin
Description: The preparation method of PRF was performed in accordance with the protocol developed by Choukroun et al 2001. PRF was withdrawn and processed from the same operated-on patient's blood; 6ml IV blood withdrawn from the antecubital vein in to two sterile 3ml red vacutainer tubes without anticoagulant, followed by a 12 minute centrifuge with 3000 RPM producing a platelet rich fibrin clot, which is then incised \& separated with 2mm basal layer of RBCs rich in growth factors
Study: NCT04924634

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress Levels and Mental Well-Being assessment
Description: At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
Study: NCT05658471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Research E-Cigarette (SREC)
Description: Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Research E-Cigarette (SREC)
Description: Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over the Counter E-Cigarette (EC)
Description: Usual brand e-cigarettes will be provided at the hospital stay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over the Counter E-Cigarette (EC)
Description: Usual brand e-cigarettes will be provided at the hospital stay.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biological Samples
Description: Blood, urine, and expired carbon dioxide will be obtained during the course of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biological Samples
Description: Blood, urine, and expired carbon dioxide will be obtained during the course of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking-related Questionnaires
Description: Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking-related Questionnaires
Description: Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays.
Study: NCT06344169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebacoyl Dinalbuphine Ester
Description: SDE will be dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: A single dose of morphine (0.15mg) will be administered along with bupivacaine during spinal anesthesia.
Study: NCT06164457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePROM Survey
Description: The APPROACH ePROM survey consists of several well validated PROM instruments, including the Seattle Angina Questionnaire 7-item version,\[4\] the EuroQol EQ5D-5L,\[5\] the Medical Outcomes Study Social Support Scale (8 item version),\[6\] the Patient Health Questionnaire 2-item and 9-item (PHQ2/9) depression screening tools\[7\], and the Self-Care of Coronary Heart Disease Inventory (SC-CHDI-V3).\[8\]
Study: NCT06336421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: VR Box brand virtual reality glasses were used in primiparous pregnant women undergoing cesarean section.~During the cesarean section, the researcher showed the pregnant woman in the experimental group a video accompanied by music and baby pictures using virtual reality glasses for an average of 10 minutes.
Study: NCT04912453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary anastomosis
Description: At laparotomy, the diseased segment of intestine will be resected and the patients will then receive primary anastomosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enterostomy
Description: At laparotomy, the diseased segment of intestine will be resected and the patients will then receive enterostomy
Study: NCT05768347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
Description: Tissue samples are harvested, prepared and cryopreserved from post Bacillus Calmette-Guerin (BCG) bladder biopsies.
Study: NCT05096481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV
Description: The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
Study: NCT05193513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hybrid expanders
Description: tow maxillary hybrid expanders supported anteriorly with tow miniscrews

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hybrid expanders
Description: tow maxillary hybrid expanders supported anteriorly with tow miniscrews
Study: NCT05096481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Diphtheria Vaccine
Description: Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
Study: NCT05995938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfullnes-Based Cognitive Therapy
Description: Mindfullnes-Based Cognitive Therapy Effect on Adherence to Immunosuppressive Therapy in Liver Transplant Recipients
Study: NCT06220162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide in combination with venetoclax and azacitidine (VAC)
Description: Enrolled patients were given chidamide 10 mg every day on days 1-14, azacitidine 75mg/m2 every day on days 1-7, and oral venetoclax began at 100mg on day 1 and increased stepwise over 3 days to reach the target dose of 400mg (100mg, 200mg, and 400mg) on days 1-28. Dose adjustments for concomitant venetoclax with CYP3A4 inhibitors were made according to the literature.
Study: NCT05614726

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase
Description: A multi-strain probiotic blend

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase
Description: A multi-strain probiotic blend
Study: NCT03901001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus and oseltamivir
Description: Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
Study: NCT06245421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DM934
Description: 1 drop in each eye, 4 to 6 times per day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Théalose
Description: 1 drop in each eye, 4 to 6 times per day